NPI 1902991706: Open Payments
NPI 1902991706. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,300 in 65 payments from 9 companies in 2025. Trend: 2023 $2,370 · 2024 $2,535 · 2025 $1,300
Food & beverage: $1,189Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $327 |
| Alkermes, Inc. | 10 | $230 |
| Vanda Pharmaceuticals Inc. | 15 | $188 |
| ABBVIE INC. | 11 | $176 |
| Janssen Pharmaceuticals, Inc | 5 | $110 |
| Neurocrine BioSciences, Inc. | 4 | $102 |
| Lundbeck LLC | 3 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
Products named: ARISTADA, VRAYLAR, HETLIOZ, UZEDY, INVEGA SUSTENNA, INGREZZA, REXULTI, AUSTEDO XR.
